Supernus Pharmaceuticals Inc (SUPN) VP Sells $191,950.00 in Stock
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 5,500 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total transaction of $191,950.00. Following the completion of the sale, the vice president now directly owns 43,887 shares of the company’s stock, valued at $1,531,656.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) traded down 1.16% during midday trading on Thursday, hitting $34.15. 475,192 shares of the stock traded hands. The company has a market capitalization of $1.72 billion, a PE ratio of 18.37 and a beta of 1.89. Supernus Pharmaceuticals Inc has a 12-month low of $17.25 and a 12-month high of $35.35. The firm’s 50 day moving average price is $32.64 and its 200 day moving average price is $27.32.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.03. The company had revenue of $57.58 million for the quarter, compared to analyst estimates of $57.91 million. Supernus Pharmaceuticals had a return on equity of 35.33% and a net margin of 43.38%. Analysts expect that Supernus Pharmaceuticals Inc will post $1.07 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Supernus Pharmaceuticals Inc (SUPN) VP Sells $191,950.00 in Stock” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/05/25/supernus-pharmaceuticals-inc-supn-vp-sells-191950-00-in-stock.html.
A number of research firms recently commented on SUPN. Stifel Nicolaus increased their price objective on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, April 3rd. Jefferies Group LLC increased their price objective on Supernus Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 8th. Cantor Fitzgerald restated a “buy” rating and issued a $31.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, March 1st. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 4th. Finally, Cowen and Company increased their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Supernus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $29.00.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. raised its stake in Supernus Pharmaceuticals by 156,173.3% in the first quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock valued at $209,595,000 after buying an additional 6,692,025 shares during the period. Russell Investments Group Ltd. bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at about $21,772,000. AXA bought a new stake in Supernus Pharmaceuticals during the first quarter valued at about $6,519,000. BlackRock Institutional Trust Company N.A. raised its stake in Supernus Pharmaceuticals by 16.8% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 1,149,244 shares of the specialty pharmaceutical company’s stock valued at $28,421,000 after buying an additional 165,346 shares during the period. Finally, Vanguard Group Inc. raised its stake in Supernus Pharmaceuticals by 6.6% in the first quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after buying an additional 156,094 shares during the period. 94.94% of the stock is currently owned by institutional investors.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.